Neurocrine Biosciences Inc (NBIX) Stock Analysis
Market Closed
Sector: Healthcare · Industry: Biological Products, (No Diagnostic Substances)
AnalystsStrong Buy36 analystsWhat's happening with NBIX
Price History
5-Year Weekly Candlestick Chart
Profile
Strong growth, profitability, financial health and valuation.
How is each axis scored?
- Valuation75/100 · Strong
- P/E vs own history (10th pct)25/25
- FCF yield (6.0%)20/25
- P/S (4.5x)20/25
- EV/EBIT (n/a)10/25
- Growth100/100 · Strong
- Revenue CAGR (26.0%)25/25
- Net income CAGR (52.0%)25/25
- EPS CAGR 5Y (50.3%)25/25
- Fwd implied growth (36.1%)25/25
- Profitability95/100 · Strong
- ROIC (29.8%)25/25
- ROE (19.6%)20/25
- Net margin (21.6%)25/25
- Operating margin (25.4%)25/25
- Financial Health93/100 · Strong
- Altman Z (6.53)25/25
- Current ratio (2.93)25/25
- Interest coverage (6.8x)18/25
- Net cash / debt (Net cash)25/25
- Quality60/100 · Moderate
- Piotroski F (6/9)15/25
- Beneish M (-2.47)20/25
- FCF conversion (124%)25/25
- Margin stability (σ 383.1%)0/25
About Neurocrine Biosciences Inc
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Show more
Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Headquarters: SAN DIEGO, CA · Employees: 2,500 · Website ↗
Insider Transactions
Recent SEC Form 4 filings
- SellOpen market sale · filed 2026-09-15-826 sh2026-09-14
- SellOpen market sale · filed 2026-09-15-2311 sh2026-09-14
- SellTax withholding · filed 2026-09-15-2419 sh2026-09-11
- BuyGrant / award · filed 2026-09-15+4.5K sh2026-09-11
- SellTax withholding · filed 2026-09-15-1936 sh2026-09-11
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
75B+P/E (TTM)21.2xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 5Y history: 15.9x–843.0x · 10th pct
P/FCF16.2xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.0%A
Grade A: ValueTTM FCF / Market Cap — vs own 5Y history: 1.0%–6.4% · 98th pct
P/S (TTM)4.49xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 3.7x–9.7x · 3rd pct
EV/EBITDA16.5xB
Grade B: FairEnterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales4.1xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.6xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio4.09xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.48A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
95A+ROIC29.8%A
Grade A: MoatNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE19.6%C
Grade C: AverageReturn on Equity. Neg. equity = heavy buybacks
ROA14.7%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin21.6%A
Grade A: HighNet Income / Revenue
Operating Margin25.4%A
Grade A: HighTTM EBIT / TTM Revenue
Gross Margin98.2%A
Grade A: PremiumGross Profit / Revenue
FCF Margin26.8%A
Grade A: HighFCF / Revenue
True FCF Margin19.6%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
93A+Altman Z-Score6.53A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.93xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.07xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage6.8xC
Grade C: OkEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity0.00xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Growth
100A+Revenue CAGR26.0%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR52.0%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)50.3%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth36.1%A
Grade A: HighImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)+5.3%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income33.2%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue7.2%C
Grade C: MedTTM stock-based comp / TTM Revenue
Quality
2/10 Loss Years60BPiotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.47A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion124.3%A
Grade A: StrongFCF / Net Income
Margin Stability383.1%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue1.0%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.62xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
More metrics — Per Share, Balance Sheet, MarketHide additional metrics
Per Share
EPS (TTM)$6.47
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$14.79
Cash & short-term investments per share (Finnhub)
Book Value / Share$32.50
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$1.32B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$3.41B
Shareholders' equity (book value)
Asset / Liability3.27xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$13.94B
Current Market Capitalization
Beta0.36B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
Company is effectively debt-free after netting cash. · Current P/E of 21.2x sits at the 10th percentile of its historical range.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 25, 2026
Key Insights: Neurocrine Biosciences Inc (NBIX)
Piotroski F-Score of 6/9 indicates mixed fundamentals for Neurocrine Biosciences Inc. Altman Z-Score of 6.53 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.47 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 26% annually, with net income growing about 52% per year — a strong growth profile.
- Neurocrine Biosciences Inc converts about 27% of revenue into free cash flow — strong cash generation.
- Company is effectively debt-free after netting cash.
- Neurocrine Biosciences Inc posted a net loss in 2 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 75/100, NBIX trades near the cheapest end of its own historical range (P/E 21.2).
See how NBIX ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for NBIX in the last 30 days.
See NBIX move history →Frequently Asked Questions about NBIX
Is NBIX stock a buy right now?
PreMarketPrice's quantitative model rates Neurocrine Biosciences Inc's financial health at 93/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is NBIX stock overvalued?
Neurocrine Biosciences Inc trades at a trailing P/E of 21.2 and our valuation score rates it 75/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Neurocrine Biosciences Inc report earnings?
No confirmed earnings date is currently scheduled for NBIX. The Earnings section lists recent reports and updates as dates are announced.
What sector does Neurocrine Biosciences Inc operate in?
Neurocrine Biosciences Inc operates in the Healthcare sector, within the Biological Products, (No Diagnostic Substances) industry. The Related Stocks section lists sector peers for comparison.
What does Neurocrine Biosciences Inc do?
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders.
About Neurocrine Biosciences Inc (NBIX) Stock
Neurocrine Biosciences Inc (NBIX) is a US-listed stock operating in the Healthcare sector, specifically the Biological Products, (No Diagnostic Substances) industry. Real-time pricing data for Neurocrine Biosciences Inc is available on this page with a market capitalization of $13.9 billion. The financial health score for NBIX is 93/100, which indicates excellent financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for NBIX stock.
NBIX Stock Analysis & Key Metrics
On PreMarketPrice, you can track Neurocrine Biosciences Inc (NBIX) across multiple dimensions:
- Pre-market price & movement: Real-time NBIX stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for NBIX with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Neurocrine Biosciences Inc across multiple reporting periods.
- Financial health score: A composite score of 93/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for NBIX.
- Sector peers: Compare NBIX against 10 other healthcare stocks on key financial metrics.
Is NBIX a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Neurocrine Biosciences Inc (NBIX) as an investment. The financial health score of 93/100 suggests excellent financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Neurocrine Biosciences Inc (NBIX) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.